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Abstract
Objective
To characterize the phenotype of patients with symptoms of periodic paralysis (PP) and
ryanodine receptor (RYR1) gene mutations.
Methods
Cases with a possible diagnosis of PP but additional clinicopathologic ﬁndings previously
associated with RYR1-related disorders were referred for a tertiary neuromuscular clinical
assessment in which they underwent detailed clinical evaluation, including neurophysiologic
assessment, muscle biopsy, and muscle MRI. Genetic analysis with next-generation sequencing
and/or targeted Sanger sequencing was performed.
Results
Three cases with episodic muscle paralysis or weakness and additional ﬁndings compatible with
a RYR1-related myopathy were identiﬁed. The McManis test, used in the diagnosis of PP, was
positive in 2 of 3 cases. Genetic analysis of known PP genes was negative. RYR1 analysis
conﬁrmed likely pathogenic variants in all 3 cases.
Conclusions
RYR1 mutations can cause late-onset atypical PP both with and without associated myopathy.
Myalgia and cramps are prominent features. The McManis test may be a useful diagnostic tool
to indicate RYR1-associated PP. We propose that clinicopathologic features suggestive of
RYR1-related disorders should be sought in genetically undeﬁned PP cases and that RYR1 gene
testing be considered in those in whom mutations in SCN4A, CACNA1S, and KCNJ2 have
already been excluded.
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The skeletal muscle ryanodine receptor (RYR1) gene enc-
odes the principal sarcoplasmic reticulum calcium release
channel with a crucial role in excitation-contraction coupling.
Mutations in RYR1 are the most common genetic cause of
nondystrophic neuromuscular disorders,1,2 associated with
a wide spectrum of clinicopathologic features, ranging from
various early-onset congenital myopathies—central core
disease,3 multiminicore disease (MmD),4 centronuclear
myopathy,5 and congenital ﬁber type disproportion6—to the
malignant hyperthermia (MH) susceptibility trait. RYR1
mutations may also give rise to episodic neuromuscular
manifestations, including exertional myalgia and rhabdo-
myolysis,7 a late-onset axial myopathy,8,9 and have recently
been associated with a novel bleeding disorder due to ab-
normal smooth muscle cell contractility.10 Episodes of atyp-
ical periodic paralysis (PP) have been previously reported in
a single patient with a recessive RYR1-related myopathy,11
but it has been unclear whether this phenotype was unique to
the reported individual or common across diﬀerent RYR1
genotypes. The association between RYR1 and PP is not
entirely unexpected, considering that dysfunction of Cav1.1,
the other key player involved in excitation-contraction cou-
pling and the principal RYR1 interactor, is the most common
cause of primary PP. Recently, both dominant and recessive
families with a Cav1.1-related myopathy have been de-
scribed,12 suggesting further phenotypic overlap between
RYR1 and Cav1.1 dysfunction and a continuum between
myopathic and episodic phenotypes due to mutations in
these genes. Here, we report 3 additional RYR1-mutated
patients presenting with PP episodes and variable additional
myopathic manifestations.
Methods
We examined cases referred with a possible diagnosis of PP
but additional clinicopathologic ﬁndings previously associated
with RYR1-related disorders to the national referral center for
skeletal muscle channelopathies in the United Kingdom and
to the Swiss Neuromuscular Diseases Unit Center.
Standard protocol approvals, registrations,
and patient consents
All procedures were conducted as part of routine clinical care.
The study was performed under the ethics guidelines issued
by our institution, with written informed consent obtained
from all participants for genetic studies.
Genetic analysis for PP genes SCN4A,CACNA1S, andKCNJ2
was performed at the Neurogenetics Unit, National Hospital
for Neurology and Neurosurgery as provided by the
Channelopathy Highly Specialized National Service for rare
disease. Samples underwent next-generation sequencing on
an Illumina HiSeq after enrichment with an Illumina custom
Nextera Rapid Capture panel (Illumina, Inc, San Diego, CA).
For case 2, the library preparation and enrichment were
performed with TruSight One kit (Illumina) according to
protocol instructions, allowing analysis of a panel of ≈5,000
genes (including PP genes and RYR1). The library was
quantiﬁed with the Qubit 2.0 Fluorometer system (Thermo
Fisher Scientiﬁc, Waltham, MA), and 2 × 250-bp paired-end
sequencing was performed on the MiSeq sequencer
(Illumina), as well as sequences alignment (Burrows-Wheeler
aligner) and variant calling (Genome Analysis Toolkit variant
caller). The variants were then analyzed with VariantStudio
(Illumina).
Additional targeted RYR1 Sanger sequencing of all cases was
performed at the Diagnostic DNA Laboratory at Guy’s
Hospital, London.
Results
Case 1
A 54-year-old man was born 7 weeks prematurely. An atrial
septal defect was noted at birth and corrected at the age of
5 years. Walking was delayed until the age of 2 years. He was
never able to run or to keep up with peers physically because
of weakness of his arms and legs. In early childhood, he toe-
walked, ultimately requiring Achilles tendon lengthening.
Symptoms were eﬀectively stable throughout childhood, but
from the age of 20 years, there was slowly progressive proxi-
mal weakness.
At the age of 34 years, after a ﬂu-like illness, he complained of
a change in symptoms. He reported episodes of sudden severe
myalgia followed by profound muscle weakness in either
1 limb or the entire body from the neck down lasting for
several hours. Examination demonstrated a waddling gait and
pronounced lumbar lordosis and mild dysmorphic features
with a long thin face and high arched palate. Mild bilateral
ptosis with a complex ophthalmoplegia most marked on
upgaze, a typical ﬁnding in recessive RYR1-related myo-
pathies, was noted. There was bilateral facial and sternoclei-
domastoid weakness with additional proximal upper and
lower limb weakness. Reﬂexes were 1+, and there were no
sensory abnormalities. Cardiac examination demonstrated
atrial ﬁbrillation for which he underwent cardioversion. Be-
cause of the change in symptoms, a muscle biopsy was per-
formed. Although core-like structures were seen, they
were not felt to be typical of central core disease, a common
Glossary
CAMP = compound muscle action potential; MH = malignant hyperthermia; MmD = multiminicore disease; PEG =
percutaneous endoscopic gastrostomy; PP = periodic paralysis; RYR1 = ryanodine receptor.
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RYR1-related myopathy, and no deﬁnitive diagnosis was
reached (ﬁgure 1).
From this point, he continued to complain of episodes of tem-
porary worsening of limb weakness 2 to 3 times a year lasting for
several days. He could identify no speciﬁc triggers. At the age of
38 years, he presented with an episode of severe neck ﬂexor and
bulbar weakness. Over the course of 9 days, his neck ﬂexor
weakness improved to baseline. Bulbar function remained im-
paired, and a percutaneous endoscopic gastrostomy (PEG) tube
for feeding was inserted. However, he continued to report ﬂuc-
tuant improvement in his swallow, on some days being entirely
reliant on the PEG and on others managing a soft diet. Fourteen
months after the PEG insertion, he attended clinic and reported
that he no longer used it and consistentlymanaged a normal diet.
Videoﬂuoroscopy demonstrated only minor persisting abnor-
malities, and the PEG was removed at his request.
Over subsequent years, he continued to experience acute attacks
of myalgia followed by weakness. When care was transferred to
us, he was reinvestigated, including a repeatmuscle biopsy at the
age of 42 years (ﬁgure 2), which on this occasion revealed mild
loss of oxidative enzyme activity in the central region of many
ﬁbers, but classic central cores were not observed.
Electrophysiologic tests showed myopathic EMG features,
normal repetitive stimulation, mildly abnormal jitter, and oc-
casional blocking on single-ﬁber EMG (including in extensor
digitorum communis, biceps, and orbicularis oculi). While
indicative of a mild neuromuscular junction transmission de-
fect, this was thought likely to be a secondary phenomenon
rather than a primary myasthenic feature.13 Serologic testing
for acetylcholine receptor antibodies and muscle-speciﬁc ki-
nase antibodies was negative. The McManis test for PP was
positive on 2 separate occasions (53% and 59% decrement in
Figure 1 Histology slides of muscle biopsies taken from case 1 at age (A) 34 and (B) 42 years
(A) Histologic examination of a right quadriceps muscle biopsy performed at age 34 years showed variation in fiber diameter and internalized nuclei with
hematoxylin and eosin staining. (B) ATPase histochemistry at pH 4.3 indicated type I fiber predominance with decreased myofibrillar ATPase activity in core-
like areas in up to 15% of type I fibers (red arrow). (C) Central absence of staining suggestive of cores was apparent in type I and II fibers in the nicotinamide
dinucleotide tetrazolium reductase preparation (black arrows), and central reduction in oxidative enzyme activitywas confirmedby succinate dehydrogenase
staining (D, black arrow). Scale bar in A represents 100 μm in (A) and (C), 200 μm in (B), and 50 μm in (D).
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compound muscle action potential [CMAP] amplitude). MRI
demonstrated fatty inﬁltration of all thigh muscles, in particular
the adductor magnus, which was almost completely replaced
by fat, with relative sparing of the vastus lateralis, rectus femoris,
gracilis, and semitendinosus, a pattern of selective involvement
previously associated with RYR1-relatedmyopathies.14,15 There
was no family history of similar symptoms. Genetic analysis
revealed RYR1 variants Arg109Trp, previously described
with MmD and ophthalmoplegia,4,16 a variant of uncertain
signiﬁcance Met485Val,4 and the novel although presumed
truncating variant Gln70X. Testing for congenital myasthenia
and PP genes was negative. His unaﬀected mother carried the
Gln70X variant. It was not possible to obtain DNA from his
father.
Case 2
A 42-year-old Swiss woman presented with intermittent
weakness of the limbs lasting from several minutes to 2 days.
Figure 2 Histologic examination of a right biceps muscle biopsy
Histologic examination of a right biceps muscle biopsy performed at age 42 years showed (A) variation in fiber diameter and increased internal nuclei with (B)
occasional fibers showing central basophilia (arrow) and (C) a small number of necrotic fibers.Gomori trichrome staining suggested regions with reduced
mitochondrial staining (arrow). (E) ATPase histochemistry indicated focal type I fiberpredominance (darkly stained fibers). (F)Mild central pallor suggestive of cores
was apparent in type I and II fibers in the nicotinamide adenine dinucleotide tetrazolium reductase preparation (arrows), and (G) central reduction in oxidative
enzyme activity was confirmed by cytochrome oxidase histochemistry. Scale bar in represents 260 μm in (E); 100 μm in (A), (F), and (G); and 50 μm in (B–D).
e4 Neurology | Volume 90, Number 5 | January 30, 2018 Neurology.org/N
Medical history was notable for migraine and 3 caesarean
sections. The ﬁrst episode of ﬂaccid paresis occurred during
her ﬁrst pregnancy at the age of 23 years with a fall from the
couch when she could not move her right arm and leg for
several minutes, without associated disturbance of cognition
or sensory symptoms. Examination at the emergency room
after recovery was normal. Brain imaging was not performed
because of the pregnancy. Two subsequent EEGs were nor-
mal, and no speciﬁc diagnosis was made at the time. She had
a history of migraine, and we cannot deﬁnitively exclude the
possibility that this ﬁrst episode of unilateral weakness was
a migraine aura without headache. However, her typical mi-
graine episodes are headache and are distinct from this pre-
sentation. Fifteen years later, while driving, she noted
weakness of her arms, legs, and trunk severe enough to war-
rant stopping the car. Weakness recovered slowly after 15
minutes. A similar episode occurred a few months later. Po-
tassium levels and clinical examination when asymptomatic
were normal. Subsequently, the frequency of similar episodes
with ﬂaccid paresis of her limbs, aﬀecting predominantly the
legs and lasting several minutes, increased and they occurred
daily, always after resting. No correlation with food intake or
fasting was reported. In addition, she complained of painless
cramps in her arms and legs muscles, which could become
painful if she tried to stretch her muscles. These lasted up to
10 minutes and also occurred during sleep.
A detailed neurologic examination at the age of 42 years
revealed no abnormalities. A relatively thin and long face with
a small lower jaw was noted, but she was not overtly dys-
morphic. On follow-up examination, she presented with
ﬂaccid weakness of her right hand lasting for 2 days. Motor
and sensory nerve conduction studies, repetitive motor nerve
stimulation, and EMG in the limbs and paravertebral muscles
performed after recovery from the acute episode were un-
remarkable. The McManis test was negative. Laboratory
testing revealed no thyroid dysfunction; electrolytes and
creatine kinase were normal. Muscle biopsy of the tibialis
anterior muscle was unremarkable. Genetic testing revealed
RYR1 gene variants Arg1507Gln and Gly2446Ser in trans.
Arg1507Gln is a missense variant with a minor allele fre-
quency of 0.00001 in ExAC that has been previously found in
other myopathic phenotypes. Gly2446Ser, although not
previously reported, localizes to a recognized MH-associated
mutational hot spot (www.emhg.org). PP gene testing was
negative.
Case 3
This 49-year-old man reported experiencing episodes of mi-
nor limb weakness after strenuous exercise that lasted a few
hours from the age of 14 years. He had his ﬁrst full attack of
muscle paralysis at the age of 29 years. He awoke in the
morning after a day of strenuous exercise to ﬁnd that he was
unable to walk. From this age on, he experienced multiple
similar episodes. All muscles from the neck down could be
weak, although the legs were predominantly and most
severely aﬀected. Symptoms usually lasted for several hours
but could persist for as long as 48 hours. In the recovery phase,
he reported that the limbs could be painful as strength
returned. Symptoms could be provoked by exercise, intense
heat, or a carbohydrate-rich meal late at night.
Medical history was notable for 2 complicated general anes-
thetics in childhood, although the exact circumstances were
unclear and medical records unavailable. His parents were
advised after these that he may be at risk of MH and to inform
clinicians before any future procedures requiring general
anesthesia.
Examination was unremarkable, as was creatine kinase and
MRI of the lower limbs. EMG and nerve conduction study
were normal, but theMcManis test for PP was positive with an
exercise-induced reduction of CMAP of 68%. A biopsy of the
tibialis anterior muscle demonstrated variation in ﬁber size, an
increase in internal nuclei, and 1 ring ﬁber (ﬁgure e-1, http://
links.lww.com/WNL/A96). A type I ﬁber predominance was
interpreted as normal for the muscle biopsied. Genetic testing
for PP genes was negative, but an RYR1 variant Arg1043His
was identiﬁed. Another amino acid substitution at the same
site, Arg1043Cys, previously associated with the MH trait but
not functionally tested yet (www.emhg.org), has been
described.
Discussion
We have previously reported a single patient with recessive
RYR1-related MmD with additional episodic muscle weak-
ness/paralysis.11 Here, we have described 3 additional cases
(summarized in the table). One was compound heterozygous
for RYR1 nonsense and missense mutations and presented
with later development of episodic symptoms in the context of
a congenital myopathy, similar to our original patient reported
by Zhou et al.17 who showed a comparable genotype and
phenotype. The other 2 patients had an episodic phenotype
without myopathy and were either heterozygous for or com-
pound heterozygous forRYR1missensemutations (putatively)
implicated in the MH trait, suggesting tentative genotype-
phenotype correlations. In all cases (including our original
case), the onset of episodic muscle paralysis was from early
adulthood onward, which is later than the onset typically seen
in primary PP.17 Although there were variable triggers, in-
cluding exertion or rest after exertion, which is a typical trigger
for PP, there was no consistent relationship to food or tem-
perature across all the cases. Myalgia or cramp was a universal
feature, indicating overlap with the spectrum of RYR1-related
exertional myalgia/rhabdomyolysis, and this, together with the
later age at onset, may be a phenotypic clue for future cases.
The McManis test was positive in 2 of 3 of our new cases. We
retrospectively reviewed the source data for our previously
reported case11 and found that the drop in CMAP amplitude
when calculated from the postexercise increment was also
>40%, indicating a positive test.
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A positive McManis test, to the best of our knowledge, has
previously been described only in primary or secondary
PP.18 Given the direct interaction between the Cav1.1
channel implicated in the majority of cases of hypokalemic
PP19 and RYR1, it seems plausible that dysfunction of each
may produce phenotypic mimics. This is supported by the
observation of a profound disturbance of the normal
Cav1.1/RYR1 interaction in 1 previous patient with RYR1-
related PP and other patients with recessive RYR1-related
myopathies.11,20 Furthermore, the recently described CAC-
NA1S-associated early-onset myopathy shares features of
predominantly axial weakness and ophthalmoplegia with
RYR1-related myopathies12 and may also feature similar
reductions of the Cav1.1 protein. However, the exact
mechanism by which the RYR1 variants would cause an
episodically unexcitable sarcolemma as demonstrated by
a positive McManis test is unclear. On the basis of the recent
observation of altered BK channel activity in RYR1-mutated
smooth muscle cells,10 one possibility is via an impairment of
BK channel–mediated membrane repolarization due to
altered intracellular calcium homeostasis, but this requires
further study.10,21,22
Other atypical PP phenotypes associated with motor neurop-
athy due to mitochondrial gene mutations have been
described,23 demonstrating that the clinical symptoms may be
seen in non–ion channel genetic disorders. Our data demon-
strate that late-onset episodic muscle weakness or paralysis
with prominent myalgia and cramps may be a more common
RYR1-associated phenotype than the single case we previously
reported and may not be limited to a speciﬁc genotype. We
suggest that cases compound heterozygous for RYR1 nonsense
and missense mutations are more likely to have a concomitant
early-onset myopathy. The McManis test may be a useful di-
agnostic tool in these cases, although a negative test does not
exclude the possibility of RYR1 involvement.
We propose that clinicopathologic features suggestive of
RYR1 disorders should be sought in genetically undeﬁned PP
cases and RYR1 gene testing considered in those in whom
mutations in SCN4A, CACNA1S, and KCNJ2 have already
been excluded.
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Table Summary of clinicopathologic features of cases with RYR1 gene variants and episodic weakness/paralysis
Symptoms Examination
CK,
IU/L EMG
McManis
test Muscle biopsy
RYR1
variants
Previously
reported
case11
Hypotonia, respiratory and
feeding impairment at birth;
delayed motor milestones;
episodic limb weakness
lasting days from age 18 y;
cold- and exercise-induced
myalgia/cramp from age 26 y
High arched palate;
facial weakness;
ophthalmoplegia;
severe trunk and neck
weakness; moderate
limb weakness;
hyperlordosis
Normal
range
Myopathic Positive Variation in fiber
size; increased
internal nuclei;
core-like structures
Asp708Asn;
Arg2241X;
Arg2939Lys
Case 1 Delayed walking; early onset
proximal myopathy; episodic
myalgia followed by limb and
neck weakness lasting hours
to days from age 34 y;
fluctuant bulbar weakness
Long thin face; high
arched palate; proximal
myopathy; facial
weakness and ptosis;
ophthalmoplegia;
hyperlordosis
101 Myopathic;
increased
jitter and
blocking on
SFEMG
Positive Variation in fiber
size; increased
internal nuclei;
areas of central
pallor suggestive of
core-like structures
Gln70X;
Arg109Trp;
Met485Val
Case 2 Early history and
development normal;
episodic limb weakness from
age 23 y; cramps with
myalgia
Long thin face 120 Normal Negative Normal Arg1507Gln;
Gly2446Ser
Case 3 Early history and
development normal; minor
episodic weakness from age
14 y; episodic limb paralysis
and myalgia from age 29 y
Normal 92 Normal Positive Type 1
predominance; 1
ragged red fiber
(+COX negative);
increased internal
nuclei; 1 ring fiber
Arg1043His
Abbreviations: CK = creatine kinase; SFEMG = single-fiber EMG.
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